Trials / Completed
CompletedNCT04655677
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.
Detailed description
The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Baseline testing, Lymphodepleting, C-CAR039 infusion, and Follow-up Visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Prizloncabtagene Autoleucel | Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2024-02-28
- Completion
- 2024-06-30
- First posted
- 2020-12-07
- Last updated
- 2025-05-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04655677. Inclusion in this directory is not an endorsement.